Celcuity Inc.

NASDAQ: CELC · Real-Time Price · USD
51.86
-0.03 (-0.06%)
At close: Aug 15, 2025, 3:59 PM
51.11
-1.45%
After-hours: Aug 15, 2025, 07:38 PM EDT

Company Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States.

The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.

It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.

Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Inc.
Celcuity Inc. logo
Country United States
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 87
CEO Brian F. Sullivan

Contact Details

Address:
16305–36th Avenue North
Minneapolis, Minnesota
United States
Website https://www.celcuity.com

Stock Details

Ticker Symbol CELC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001603454
CUSIP Number 15102K100
ISIN Number US15102K1007
Employer ID 00-0000000
SIC Code 8071

Key Executives

Name Position
Brian F. Sullivan Co-Founder, Chairman & Chief Executive Officer
Vicky Hahne CPA Chief Financial Officer
Brent Eilefson General Counsel
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, Vice President, Secretary & Director
Eldon C. Mayer III, M.B.A. Chief Commercial Officer
Igor Gorbatchevsky M.D. Chief Medical Officer
Sheri Smith Acting Head of Clinical Operations

Latest SEC Filings

Date Type Title
Aug 14, 2025 10-Q Quarterly Report
Aug 14, 2025 8-K Current Report
Aug 04, 2025 SCHEDULE 13G Filing
Aug 04, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 01, 2025 3 Filing
Aug 01, 2025 SCHEDULE 13D Filing
Aug 01, 2025 8-K Current Report
Jul 31, 2025 305B2 Filing
Jul 31, 2025 8-K Current Report
Jul 31, 2025 424B5 Filing